Gareth Morgan, MD, FRCP, FRCPath, PhD, from the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, talks to us about current cutting-edge therapies in the potential treatment of melanoma. He describes that the use of immune checkpoint inhibitors with CAR T-cells appears particularly promising, as their combination has been shown to enhance their activity in treating melanoma. A need to shift focus from multiple myeloma to other diseases is also needed, as stated by Prof. Morgan, to understand the structure of the disease microenvironment as a way of predicting patients’ responses to different immunotherapies. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.